Thursday, November 12, 2026

U.S. Ratings Firm's Dual Role Echoes Global Conflict-of-Interest Debate

The Oasis Group rates wealth management and estate planning vendors while selling consulting services to the same market — a structural conflict regulators worldwide have scrutinized since 2008. The firm's 2026 Peaks for Estate Planning Platforms report is widely cited in fintech circles, raising questions about independence that remain publicly unanswered. No specific incident has been identified, but analysts rate the governance risk as major severity.

LM Salvado
LM Salvado

May 31, 2026

U.S. Ratings Firm's Dual Role Echoes Global Conflict-of-Interest Debate
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The Oasis Group rates wealth management and estate planning vendors while simultaneously selling consulting services to firms in that market — a conflict-of-interest model regulators worldwide confronted after the 2008 financial crisis.1

The firm publishes the 2026 Peaks for Estate Planning Platforms report, a benchmark widely cited in fintech and estate planning circles.1 It also operates across wealth management research, market analysis, and consulting — domains that overlap directly with the vendors it rates.

The structural problem is familiar internationally. When issuers pay for their own ratings, incentive structures degrade. That lesson drove post-crisis regulatory reform of traditional credit rating agencies in the U.S., EU, and across G20 markets. Independent research firms occupy a less regulated space — making voluntary governance the only real safeguard.

The core question: can a firm that earns consulting revenue or sponsorship fees from vendors it rates credibly guarantee independent assessments?1 Even with editorial controls in place, the financial relationship creates a structural conflict that undermines trust in outcomes.

Risk analysts rate the severity as major.1 Likelihood is rated low — no specific incident has been identified. But low likelihood does not neutralize a major-severity structural exposure. The conditions for conflict exist; that is the finding.

For institutional clients globally — using these rankings to make platform procurement or investment decisions — the practical question is whether independence is verified. Without published disclosure of client relationships, firewall policies, or third-party audits, it is not.

Governance best practice in research publishing requires affirmative separation: distinct editorial and commercial teams, disclosed conflicts, and independent oversight. Whether The Oasis Group has implemented such controls is not publicly documented.1

The wealth management sector depends on third-party research to evaluate fintech vendors. Ratings credibility is the product. Erosion of that credibility carries direct consequences for the firm's market position — and for clients acting on its outputs.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com